Adults with Osteogenesis Imperfecta

Eric Orwoll, M.D., of OHSU’s Bone and Mineral Unit, is conducting an 18-month research study to determine the effectiveness and the safety of Teriparatide (Forteo™) taken “once a day” in adults (older than 18 years of age) with Osteogenesis Imperfecta. Teriparatide is taken as an injection once a day and is currently used for the treatment of osteoporosis. One out of two adults will receive active treatment (Teriparatide) for the 18-month study. Following the study period the placebo group will have the option to receive, at no cost, Teriparatide for an 18-month period.

If you are an adult 18 years or older and are not currently taking any medication now or within the last 12 months that may affect bone density, you may be eligible to participate in this study.

Qualified applicants will receive:
- Bone density testing (to see if your bones are healthy)
- Physical exams
- Laboratory testing (to monitor your health)
- Calcium and vitamin D supplements

All procedures (testing) and study drug are provided to you at no cost.

If you qualify and choose to participate in our research study, your participation is voluntary and there will be no compensation for your time or travel.

TO FIND OUT IF YOU MAY QUALIFY FOR THIS TREATMENT STUDY,
Call Sandra Veith at (503) 494–5630
or email at veithsa@ohsu.edu

eIRB #710
GCRC #859